Ponaxen 15 mg (Ponatinib) Tablets

Ponaxen 15 contains Ponatinib 15 mg, a targeted anticancer medicine used for certain Philadelphia chromosome-positive (Ph+) leukemias, including selected cases of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL).

Therapeutic Effects:
Ponatinib works by inhibiting abnormal BCR-ABL tyrosine kinase activity associated with Philadelphia chromosome-positive leukemia. By blocking this disease-driving signaling pathway, it helps reduce the growth and survival of abnormal leukemia cells.

Key Therapeutic Uses:

• Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
• Certain cases involving the BCR-ABL1 T315I mutation
• Patients requiring a targeted therapy when other tyrosine kinase inhibitors may not be appropriate

Ponatinib is a prescription medicine and should be used only under specialist medical supervision.

Active Ingredient:

• Ponatinib Hydrochloride equivalent to Ponatinib 15 mg

Dosage Form:

• Film-coated tablet

Therapeutic Class:

• Tyrosine Kinase Inhibitor (TKI)
• BCR-ABL Tyrosine Kinase Inhibitor

The tablet contains ponatinib as the active pharmaceutical ingredient along with inactive excipients used to provide the appropriate tablet structure, stability, coating, and appearance.

The appropriate Ponatinib dose varies according to the type of leukemia, treatment response, previous therapies, and individual patient factors. The prescribing oncologist determines the dose and duration of treatment.

General Administration Guidance:

• Take the tablet exactly as prescribed by your doctor.
• Swallow the tablet whole with water.
• It may generally be taken with or without food.
• Take it at approximately the same time each day.
• Do not crush, break, or chew the tablet unless specifically instructed.
• Do not change the dose or stop treatment without consulting your oncologist.

Missed Dose:
If a dose is missed, follow the instructions provided by your prescribing doctor or pharmacist. Do not take extra tablets to compensate for a missed dose unless specifically instructed.

Important: Ponatinib can cause serious adverse reactions, including cardiovascular and blood-related complications. Regular medical monitoring is important throughout treatment.